These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16932624)

  • 1. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas DT; Sidiropoulos P; Bertsias G
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):22-30. PubMed ID: 16932624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for lupus nephritis: a revisit.
    Lai KN; Tang SC; Mok CC
    Nephrology (Carlton); 2005 Apr; 10(2):180-8. PubMed ID: 15877679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lupus nephritis.
    Austin HA; Balow JE
    Semin Nephrol; 2000 May; 20(3):265-76. PubMed ID: 10855936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for resistant lupus nephritis.
    Mok CC
    Semin Arthritis Rheum; 2006 Oct; 36(2):71-81. PubMed ID: 16884971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
    Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the management of lupus nephritis: let the treatment fit the patient.
    Bertsias G; Boumpas DT
    Nat Clin Pract Rheumatol; 2008 Sep; 4(9):464-72. PubMed ID: 18756272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
    Pepper R; Griffith M; Kirwan C; Levy J; Taube D; Pusey C; Lightstone L; Cairns T
    Nephrol Dial Transplant; 2009 Dec; 24(12):3717-23. PubMed ID: 19617257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.
    Camous L; Melander C; Vallet M; Squalli T; Knebelmann B; Noël LH; Fakhouri F
    Am J Kidney Dis; 2008 Aug; 52(2):346-52. PubMed ID: 18572292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond immunosuppression - challenges in the clinical management of lupus nephritis.
    Masood S; Jayne D; Karim Y
    Lupus; 2009 Feb; 18(2):106-15. PubMed ID: 19151111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of lupus nephritis with standard therapeutic protocols and cyclosporine].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():13-8. PubMed ID: 12583308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands.
    van den Wall Bake AW; Berden JH; Derksen RH; de Glas-Vos JW; Hagen EC
    Neth J Med; 1994 Dec; 45(6):280-4. PubMed ID: 7838244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus nephritis.
    Sauter M; Anders HJ
    Minerva Med; 2007 Dec; 98(6):749-58. PubMed ID: 18299686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis.
    Mak SK; Lo KY; Lo MW; Chan SF; Tong GM; Wong PN; Wong AK
    Nephrology (Carlton); 2008 Jun; 13(4):331-6. PubMed ID: 18476916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
    Rovin BH; Parikh SV; Hebert LA; Chan TM; Mok CC; Ginzler EM; Hooi LS; Brunetta P; Maciuca R; Solomons N
    Clin J Am Soc Nephrol; 2013 Jan; 8(1):147-53. PubMed ID: 22879439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.